Thrombophilia and Coagulation Disorders Testing

July 2011

Thrombophilia

An estimated 37 million patients are affected by thrombotic disorders each year. This number will continue to rise with the increase in our aging population. For some patients, acquired risk factors, such as surgery or major trauma, may help explain the thrombotic event. When an acquired risk factor cannot be identified or when clinical and family history warrant, thrombophilia testing is recommended.

A full thrombophilia assessment includes measures of antithrombin, protein C, and protein S in addition to genetic testing for factor V R506Q Leiden and the prothrombin G20210A mutation. Lupus-like anticoagulant testing and disseminated intravascular coagulation/intravascular coagulation and fibrinolysis (DIC/ICF) assessment are also performed.

Test

Thrombophilia Profile - 83093

Hot Topic Presentation

Guidelines for Anticoagulation Therapy for Secondary Prevention After Deep Vein Thrombosis by Robert D. McBane, MD, Consultant, Division of Cardiovascular Diseases and Mayo Special Coagulation Laboratories and Coagulation Clinical Centers, Mayo Clinic

Useful For

• Evaluating patients with thrombosis or hypercoagulability states
• Detecting a lupus-like anticoagulant; dysfibrinogenemia; disseminated intravascular coagulation/intravascular coagulation and fibrinolysis (DIC/ICF)
• Detecting a deficiency of antithrombin, protein C, or protein S
• Detecting activated protein C resistance (and the factor V R506Q – Leiden mutation – if indicated)
• Detecting the prothrombin G20210A mutation